Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer

被引：8
作者：
Osterweil, Neil
机构：
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 04期
关键词：
D O I：
10.1158/2159-8290.CD-NB2022-0015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：878 / 879
页数：2
相关论文
共 50 条
  • [21] The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
    Firas Batrash
    Mahmoud Kutmah
    Jun Zhang
    Experimental Hematology & Oncology, 12
  • [22] Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
    Strickler, J. H.
    Satake, H.
    George, T. J.
    Yaeger, R.
    Hollebecque, A.
    Garrido-Laguna, I.
    Schuler, M.
    Burns, T. F.
    Coveler, A. L.
    Falchook, G. S.
    Vincent, M.
    Sunakawa, Y.
    Dahan, L.
    Bajor, D.
    Rha, S. -Y.
    Lemech, C.
    Juric, D.
    Rehn, M.
    Ngarmchamnanrith, G.
    Jafarinasabian, P.
    Tran, Q.
    Hong, D. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01) : 33 - 43
  • [23] Sotorasib for KRAS p.G12C-mutated advanced pancreatic cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (03): : 213 - 213
  • [24] WEE1 inhibition enhances anti-tumor activity of sotorasib in KRASG12C-mutated non-small cell lung cancer in preclinical models
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Yamauchi, Toyohiro
    Liu, Jie
    Ohashi, Akihiro
    Kobayashi, Susumu S.
    CANCER SCIENCE, 2023, 114 : 1043 - 1043
  • [25] Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
    Shi, Yuankai
    Fang, Jian
    Xing, Ligang
    Yao, Yu
    Zhang, Jian
    Liu, Lian
    Wang, Yongsheng
    Hu, Changlu
    Xiong, Jianping
    Liu, Zhihua
    Yang, Runxiang
    Wang, Zhen
    Zhao, Enfeng
    Wang, Mengzhao
    Zhao, Yanqiu
    Tang, Kejing
    Li, Zhihua
    Song, Zhengbo
    Li, Yongsheng
    Zhuang, Wu
    Jin, Bo
    Cheng, Ying
    Hu, Yanping
    Gu, Yanhong
    Wu, Lin
    Ma, Rui
    Yu, Qitao
    Yu, Yan
    Zhao, Jun
    Zhao, Hui
    Lv, Dongqing
    Shang, Yanhong
    Xing, Puyuan
    Zhou, Jin
    Li, Xingya
    Liu, Zhe
    Dai, Zhaoxia
    Xia, Guohao
    Chen, Xueqin
    Ba, Yi
    Bai, Chunmei
    Li, Qingshan
    An, Guangyu
    Hu, Weiguo
    Wang, Yinxiang
    Wang-Gillam, Andrea
    Ding, Yuli
    Li, Qiao
    Rao, Zhiyue
    NATURE MEDICINE, 2025, : 894 - 900
  • [26] A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
    El Saadany, Tamer
    Lupatsch, Judith E.
    Mark, Michael
    Barbier, Michaela
    Mehra, Tarun
    Schwenkglenks, Matthias
    von Moos, Roger
    SWISS MEDICAL WEEKLY, 2025, 155
  • [27] Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer
    Heng, Sarina Z. W.
    Hoo, Regina
    Tan, Daniel S. W.
    CANCER DISCOVERY, 2023, 13 (07) : 1513 - 1515
  • [28] Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
    Chen, Qi-An
    Lin, Wei-Hao
    Zhou, Xiao-Xiang
    Cao, Zheng
    Feng, Xiao-Li
    Gao, Yi-Bo
    He, Jie
    PHARMACOLOGICAL RESEARCH, 2024, 200
  • [29] Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations
    Pelster, M. S.
    Yaeger, R.
    Klempner, S. J.
    Ou, S-H. I.
    Spira, A. I.
    Janne, P. A.
    Uboha, N. V.
    Gaffar, Y. A.
    Newman, G.
    Paweletz, C. P.
    Heavey, G. A.
    Alejandro, L.
    Kheoh, T.
    Anderes, K.
    Torossian, H. Der
    Christensen, J. G.
    Weiss, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S410 - S410
  • [30] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort
    Masuishi, T.
    Strickler, J. H.
    Machiels, J-P.
    Hong, D. S.
    Greil, R.
    Chan, E.
    Hippenmeyer, J.
    Saportas, Y.
    Cardona, P.
    Xia, C.
    Kuboki, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1505 - S1505
12345